Alla studier
RekryteringFAS3INTERVENTIONELL

Extension Study for the Port Delivery System With Ranibizumab (Portal)

This study is an extension of previous research into a special eye implant called the Port Delivery System (PDS), which releases medicine (ranibizumab) slowly over time. The main goal is to see how safe this implant is in the long term for people with 'wet' age-related macular degeneration (nAMD). It's for patients who have already taken part in specific earlier studies like "Ladder," "Archway," or "Velodrome." Researchers want to understand if the PDS continues to work well and safely over many years. There are also smaller parts of the study looking at ways to handle certain side effects, such as a procedure to prevent bleeding after the implant, and checking the safety of replacing the implant if needed.

Överblick

Status
Rekrytering
Fas
FAS3
Sponsor
Hoffmann-La Roche
Inskrivningsmål
1,000
Starta
20 Sep 2018
Beräknad slutförande
31 dec 2029

Vad handlar denna studie om?

This study, called "Portal," is an important follow-up to research on a new way to treat an eye condition called 'wet' age-related macular degeneration, or nAMD. This condition affects your central vision. Instead of regular eye injections, this study uses a small, special implant that's placed in your eye during a minor surgical procedure. This implant slowly releases medicine (ranibizumab) over several months, meaning you might need fewer trips to the clinic for treatment.

The main aim of "Portal" is to check if this implant is safe and works well over a long period. It's designed for people who have already been part of previous studies about this implant, like "Ladder" or "Archway." By continuing to follow these patients, doctors can learn more about the long-term benefits and any potential side effects of this new treatment method. This helps ensure it can be a safe and effective option for many people in the future.

There are also two smaller parts of the study. One part looks at a special laser treatment called Transscleral Photocoagulation (TPC) to see if it can help prevent a rare side effect, like bleeding, that can happen after the implant is put in. The other part checks the safety of replacing the implant if it needs to be changed. Both of these mini-studies aim to make the treatment even safer and more comfortable for patients.

Viktiga punkter

  • This study is for long-term monitoring of an eye implant (PDS) for 'wet' AMD.
  • It's only for people who have been in specific previous PDS studies.
  • The implant delivers medicine to reduce the need for frequent eye injections.
  • The study checks the implant's safety and effectiveness over time.
  • Smaller parts of the study look at preventing surgical side effects and implant replacement safety.
  • You must be willing to attend all scheduled appointments.

Vem kan vara berättigad?

This study is specifically for people who have already taken part in certain previous studies about this eye implant. You would need to have completed one of those original studies, such as the "Ladder," "Archway," or "Velodrome" studies, without having left them early.

To join, you must be willing and able to come for all scheduled appointments and check-ups. If you are a woman who could become pregnant, you'll need to agree to either not have sex or use reliable birth control during the study and for a certain time afterward.

There are some reasons why you might not be able to join. For example, if you are pregnant, breastfeeding, or planning to get pregnant. Also, if you have other eye problems or serious health conditions that could make the treatment unsafe for you, or if you need to take certain medications that are not allowed in the study, you probably wouldn't be able to take part. The smaller laser sub-study has more specific rules, such as needing to have had 'wet' AMD for less than two years and having already received other eye injections.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Have I previously completed the 'Ladder,' 'Archway,' or 'Velodrome' eye implant study?
  2. Am I able and willing to attend all scheduled medical appointments for the study?
  3. If I am a woman who could become pregnant, am I willing to use effective birth control or avoid sex during the study?
  4. Am I currently pregnant or breastfeeding, or planning to become pregnant soon?
  5. Do I have any other severe eye conditions or major health issues that might prevent me from safely joining?
  6. Do I take any medications that the study rules might not allow?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

As this is an extension study, your participation will involve continued follow-up visits and assessments as determined by the study protocol. The main goal is to monitor the long-term safety and effectiveness of the PDS implant. This will include regular eye examinations, vision tests, and possibly scans of your eye. You will continue to have the ranibizumab medicine delivered by the implant, and the device will be refilled periodically. The exact number and frequency of visits, as well as the total duration of your participation, will depend on which previous study you participated in and if you join any of the sub-studies. For example, participants in the re-implantation sub-study could be followed for up to 72 weeks after their implant is replaced. You will be closely monitored for any side effects.

Potentiella risker och fördelar

Participating could offer the potential benefit of continued long-term treatment for your 'wet' AMD with potentially fewer visits for injections. However, as with any medical procedure, there are potential risks, including those associated with eye surgery and the medication itself. These might include eye irritation, implant-related issues, or changes to vision. The laser sub-study also carries a small risk of issues related to the laser treatment. You will receive detailed information about all potential risks before deciding to join. Remember, taking part in any study is completely voluntary, and you are free to withdraw at any time without affecting your usual medical care.

Locations (165)

  • Retinal Research Institute, LLC
    Verifierat postnummer
    Phoenix, USA· Avslutad
  • Arizona Retina and Vitreous Consultants
    Verifierat postnummer
    Phoenix, USA· Avslutad
  • Barnet Dulaney Perkins Eye Center
    Verifierat postnummer
    Phoenix, USA· Aktiv men inte rekryterande
  • Associated Retina Consultants
    Verifierat postnummer
    Phoenix, USA· Avslutad
  • Retinal Consultants of Arizona
    Verifierat postnummer
    Phoenix, USA· Avslutad
  • California Retina Consultants
    Verifierat postnummer
    Bakersfield, USA· Avslutad
  • Retina-Vitreous Associates Medical Group
    Verifierat postnummer
    Beverly Hills, USA· Avslutad
  • The Retina Partners
    Verifierat postnummer
    Encino, United States· Aktiv men inte rekryterande
  • Jacobs Retina center at the Shiley eye Institute UCSD
    Verifierat postnummer
    La Jolla, USA· Avslutad
  • Jules Stein Eye Institute/ UCLA
    Verifierat postnummer
    Los Angeles, USA· Avslutad
  • N CA Retina Vitreous Assoc
    Verifierat postnummer
    Mountain View, USA· Avslutad
  • Retina Consultants, San Diego
    Verifierat postnummer
    Poway, United States· Avslutad

Vanliga frågor

What is 'wet' age-related macular degeneration (nAMD)?

'Wet' AMD is an eye condition that affects the central part of your vision, making everyday tasks like reading or recognising faces difficult. It happens when abnormal blood vessels grow in the eye and leak fluid.

What is the Port Delivery System (PDS) implant?

It's a tiny, refillable device placed in your eye that releases medicine slowly over time, aiming to reduce the number of direct eye injections you might need for 'wet' AMD.

Why is this study only for people from previous studies?

This 'extension' study builds on earlier research. It helps doctors understand how the implant works over many years in people who have already safely used it, gathering long-term safety and effectiveness information.

What is ranibizumab?

Ranibizumab is a medicine used to treat 'wet' AMD. It works by blocking a protein that causes the abnormal blood vessels to grow and leak in the eye.

Måste jag betala för att delta i studien?

Clinical trials generally cover the costs of study-related treatments and visits. You should always clarify any potential costs with the study team before participating.

Hur du får reda på mer

Reference Study ID Number: GR40549 https://forpatients.roche.com/ No attachments to email below.

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "Extension Study for the Port Delivery System With Ranibizuma…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.